Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $178.00 at BTIG Research

Nektar Therapeutics (NASDAQ:NKTR) had its price target upped by BTIG Research from $151.00 to $178.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price indicates a potential upside of 68.68% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Citigroup boosted their target price on shares of Nektar Therapeutics from $102.00 to $123.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Wedbush initiated coverage on Nektar Therapeutics in a report on Tuesday, March 24th. They set a “neutral” rating and a $70.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price objective on shares of Nektar Therapeutics in a report on Monday, January 26th. William Blair upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 10th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $140.00 price target on shares of Nektar Therapeutics in a research report on Friday, March 13th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Nektar Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $134.00.

Nektar Therapeutics Stock Performance

NKTR stock traded up $20.67 during mid-day trading on Monday, reaching $105.53. The company had a trading volume of 2,694,321 shares, compared to its average volume of 1,053,172. The firm has a fifty day simple moving average of $72.24 and a 200 day simple moving average of $58.31. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of -10.35 and a beta of 1.16. Nektar Therapeutics has a fifty-two week low of $7.99 and a fifty-two week high of $106.19.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($2.69) by $0.91. Nektar Therapeutics had a negative net margin of 297.07% and a negative return on equity of 380.32%. The firm had revenue of $21.81 million for the quarter, compared to analysts’ expectations of $10.44 million. As a group, analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current year.

Insider Buying and Selling at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89. Following the sale, the insider owned 21,354 shares of the company’s stock, valued at approximately $761,697.18. The trade was a 15.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Howard W. Robin sold 423 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total value of $30,879.00. Following the sale, the chief executive officer directly owned 75,489 shares in the company, valued at $5,510,697. This trade represents a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 4,470 shares of company stock worth $181,955 over the last 90 days. Insiders own 3.71% of the company’s stock.

Institutional Investors Weigh In On Nektar Therapeutics

Large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares in the last quarter. Headlands Technologies LLC purchased a new position in Nektar Therapeutics during the second quarter worth $65,000. Integrated Wealth Concepts LLC acquired a new position in shares of Nektar Therapeutics in the first quarter worth $68,000. Quarry LP purchased a new stake in shares of Nektar Therapeutics in the fourth quarter valued at $85,000. Finally, Compass Wealth Management LLC purchased a new stake in shares of Nektar Therapeutics in the third quarter valued at $88,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: 52‑week topline extension results show deepening responses (29% and 31% achieving new SALT ≤20 in the two extension arms), broad increases across SALT thresholds, high completion rate (94%), and maintained safety with twice‑monthly dosing — supports advancing rezpegaldesleukin toward late‑stage development. 52‑Week Topline Results PR Newswire
• Positive Sentiment: Market commentary and headlines tie NKTR’s rally directly to the blinded 16‑week extension results and 52‑week topline readout, reinforcing investor attention and driving buying interest. Why Are Nektar Shares Up Monday?
• Positive Sentiment: Coverage in market movers roundups highlights NKTR among top gainers after the REZOLVE‑AA update, increasing visibility to momentum and event‑driven traders. Benzinga Movers
• Neutral Sentiment: Nektar held a conference call and webcast to discuss the 52‑week topline extension results (scheduled for April 20), which provided a forum for management to contextualize the data for investors. Conference Call Notice PR Newswire
• Neutral Sentiment: Trading was temporarily halted for NKTR with the stated reason “News pending” ahead of the release — a routine market mechanism that precedes material press releases and can concentrate volume when trading resumes.
• Negative Sentiment: Multiple law firms have filed or are soliciting lead plaintiffs in securities‑class actions alleging violations tied to prior disclosures; continued legal proceedings create potential liability, distraction, and an overhang on the stock. Schall Law Firm Notice
• Negative Sentiment: Additional plaintiff‑firm notices and a recent DJS Law Group reminder highlight parallel lawsuits and the May 5 lead plaintiff deadline, reinforcing legal risk as a near‑term catalyst for volatility. DJS Law Group Notice

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.